Newsletter Tool

PM Tracker

Today’s Big News

Sep 4, 2024

Astellas Gene Therapies to turn out the lights at South San Francisco production plant

ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow

Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets

Abbott kicks off deep-brain stimulation trial in treatment-resistant depression

Bayer builds entire ‘ecosystem’ around One A Day cell health support supplement

Radiotherapy leader Novartis brings isotope production in house, builds West Coast production plant

Featured

Astellas Gene Therapies to turn out the lights at South San Francisco production plant

By Fraiser Kansteiner

Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.

ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow

By Gabrielle Masson

Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery.

Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets

By Nick Paul Taylor

Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets.

Abbott kicks off deep-brain stimulation trial in treatment-resistant depression

By Conor Hale

The FDA previously granted Abbott a breakthrough designation for aiming the technology toward the areas of the brain that regulate mood.

Bayer builds entire ‘ecosystem’ around One A Day cell health support supplement

By Andrea Park

In a bid to boost awareness and education around healthy aging while also promoting a dietary supplement tailored to that purpose, Bayer has unveiled a suite of resources tied to the recently launched supplement.

Radiotherapy leader Novartis brings US isotope production in house, builds West Coast production plant

By Angus Liu

Novartis is further bolstering its radiotherapy infrastructure with a brand-new facility and the expansion of an existing site that will bring critical production of radioactive isotopes in house in the U.S.

BioAge files for IPO, plans pair of midstage obesity trials

By Gabrielle Masson

After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public markets.

Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win

By Kevin Dunleavy

Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.

Vertex goes all in on September's bumper awareness month push

By Ben Adams

Vertex has its drugmaking fingers in many pies and is pushing awareness campaigns for three diseases this September with one unifying theme: light.

Athira's phase 2/3 Alzheimer's trial falls short, sinking stock

By Nick Paul Taylor

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.

Eli Lilly looks to expand access to Olumiant across Africa with Eva Pharma licensing deal

By Zoey Becker

Eva will make and supply the immunology drug in 49 countries across Africa under a voluntary licensing deal that falls in line with Lilly's 30x30 access to medicines initiative.

Verastem sets first awareness day for rare form of ovarian cancer

By Andrea Park

As September’s Ovarian/Gynecologic Cancer Awareness Month gets underway, Verastem Oncology is making sure at least one day of the month is dedicated specifically to low-grade serous ovarian cancer, or LGSOC.

Fierce podcasts

Don’t miss an episode

Driving flu vaccine uptake in the post pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.

The TROP2 race for supremacy

Minimizing plastics use and risk in healthcare

Resources

Whitepaper

Building a “Best Practice” Commercial Organization in Biopharma

We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned.

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.